wound healing News
-
Evaluation of CO2 fractional laser beauty machine treatment effect
The most commonly used fractional laser is CO2 fractional laser beauty machine. After more than ten years of clinical application, it can be said that CO2 fractional laser skin resurfacing treatment technology is relatively safe. As long as its therapeutic energy and action density are mastered, there are generally no obvious side effects of. Bvlaser is a professional CO2 fractional laser ...
-
SANUWAVE Health Presents dermaPACE System Treatment Study Results Showing Enhanced Localized Wound Tissue Oxygenation
SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation advanced wound care medical systems for the repair and regeneration of skin and vascular structures and the research for new applications for focused, shockwave systems in the non-medical field today presented results from a clinical case series that demonstrated improved wound healing when treated with its FDA-cleared, ...
-
SANUWAVE Rebrands to Reflect Evolved Wound Care Solutions
SANUWAVE Health, Inc. (OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, today announced its rebranding. The new brand reflects the evolution of SANUWAVE’s solutions addressing the entire wound care pathway through its portfolio of noninvasive and ...
-
Aurealis Therapeutics Publishes First Study on Four-in-One-Combination Therapy Using Live Lactococcus Lactis Expressing Three Human Therapeutic Proteins for the Treatment of Chronic Non-Healing Wounds
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. This announcement comes as the ...
-
Hydrogen Peroxide provides Clues to Immunity, Wound Healing, Tumor Biology - Puroxi
Hydrogen peroxide isn’t just that bottled colorless liquid in the back of the medicine cabinet that’s used occasionally for cleaning scraped knees and cut fingers.It’s also a natural chemical in the body that rallies at wound sites, jump-starting immune cells into a series of events. A burst of hydrogen peroxide causes neutrophils, the immune system’s first ...
-
Potential cell therapy for Epidermolysis Bullosa (EB)
In partnership with Mesoblast Limited, JCR Pharmaceuticals has filed to extend the marketing approval of TEMCELL, a mesenchymal stem cell (MSC) wound healing product for patients with Epidermolysis Bullosa (EB). JCR has received an orphan drug designation for subcutaneous treatment of TEMCELL for EB, and are currently seeking a label extension for intravenous delivery of TEMCELL in Japan. There ...
By IMAPAC
-
Creative Bioarray Launched New Fibroblast Cells
Creative Bioarray 24th, August, 2016, launched some new fibroblast cells, along with the new cells products launch, the company released a promotion activity, aiming for providing some discouts at the beginning of autumn semester. Fibroblasts cells play an important role in wound healing, and they exist to boost the healing process. Though, there is still much to be probed as one of the most ...
-
Microlyte Matrix and Microlyte Surgical featured in clinical research presented at SAWC
Imbed Biosciences is proud to announce that research conducted using Microlyte Matrix and Microlyte Surgical will be presented in a panel discussion at SAWC, a national wound healing conference. Imbed Biosciences announced today that clinical results documenting the use of its products, Microlyte® Matrix and Microlyte® SURGICAL, will be presented at the Fall Symposium on Advanced Wound ...
-
InnoTherapy America Retains Dorian Drake International as its Export Sales Representatives for Latin America and the Caribbean
InnoTherapy America, Inc., manufacturer of the InnoSeal hemostatic wound-healing pads, announced that it has retained Dorian Drake International, Inc. as it export representatives for select markets throughout Latin America and the Caribbean. The new agreement went into effect April 1, 2019. Speaking of the firm’s new representative agreement with Dorian Drake International, President of ...
-
Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting
ARLINGTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present data from a previously completed Phase 1b clinical trial of KPI-012 in a poster session at the 2022 Association ...
-
Solving The Mystery Of Long Covid – Fluidda Magazine #2
Imaging of the pulmonary vasculature is crucial for our understanding of the short- and long-term consequences of COVID-19 Prof. William Li, president and medical director of the Angiogenesis Foundation, explains during an interview in Fluidda Magazine #2. Angiogenesis and vascular imaging form a very pressing issue to emerge from this pandemic. The need for novel parameters, such as the FRI ...
By Fluidda
-
AOTI Receives China FDA Approval for Topical Wound Oxygen (TWO2) Therapy Providing Renewed Hope for World’s Largest Diabetic Foot Ulcer Population
Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today that is has received Chinese National Medical Products Administration (NMPA), commonly referred to as China FDA, approval for its unique cyclically pressurized Topical Wound Oxygen (TWO2) therapy. Making it the only advanced sustained wound healing therapeutic to have ...
-
Aurealis Therapeutics Pioneering Multiple Drug Producing Bacteria Aup-16 Dosed to The First Diabetic Foot Ulcer Patient in The Phase 1-2a Trial
Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today that the first diabetic foot ulcer (DFU) patient has been dosed with AUP-16. The trial is performed in non-healing DFU patients and is designed to evaluate the safety, tolerability and ...
-
Research Suggests COVID-19 Affects Erectile Function
"One of the repercussions of COVID-19 is its impact on men's sexual health. COVID-19 infection is expected to be associated with an increased likelihood of erectile dysfunction (ED). Considering the high transmissibility of COVID-19, ED could be a concerning consequence for a large segment of the population" https://www.ncbi.nim.nih.gov/pmc/articles/PMC8450276/. Coincidentally, DirexGroup ...
By DirexGroup
-
Symic Bio Selected for “The Best of The Liver Meeting 2018” at AASLD
SAN FRANCISCO, November 9, 2018 – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that they were selected for “The Best of The Liver Meeting 2018” at the AASLD international liver meeting and will be presenting on its liver fibrosis program at the upcoming conference in San Francisco. Symic's molecule, SBR-294, is ...
-
FDA Clears Rex Medical Bioresorbable Vascular Closure Device
August 3, 2016 — The U.S. Food and Drug Administration (FDA) has granted market clearance to Rex Medical’s bioresorbable Closer Vascular Sealing System (VSS) to achieve rapid hemostasis of femoral artery catheterizations. The vascular closure device consists of an insertion sheath, dilator and an implant contained in a delivery system. It uses a patch placed against the artery wall ...
-
Poietis announces formation of Scientific Advisory Board and appoints two first prominent Regenerative Medicine experts
Poietis, 4D Bioprinting company, announces formation of Scientific Advisory Board (SAB) and appointment of two first prominent Scientists in Regenerative Medicine. The SAB will serve as a key strategic resource to Poietis as the company expands capabilities of Next- Generation Bioprinting (NGB) platform to therapeutic applications and develops first implantable tissues such as a ...
By Poietis
-
Expansion of Topical Wound Oxygen (TWO2) Product Family Extends Treatment to Chronic Wound Patients with Larger Limbs, Venous and Diabetic Foot Ulcers
AOTI Inc. announced today an eagerly anticipated expansion of its unique multi-modality Topical Wound Oxygen (TWO2) therapy product family. The addition of a new larger extremity-chamber to the company’s peripheral vascular disease (PVD) focused product line, allows for the application of TWO2 treatments for many more patients suffering from costly nonhealing chronic wounds. Especially ...
-
Healiva Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew
Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world’s broadest portfolios of affordable, ...
By healiva SA
-
Preventing Wound Infections and Complications at Urgent Care
Cuts and lacerations are among the most common complaints that bring patients to urgent care clinics. Whether a wound originates from an accident with a sharp object, such as a kitchen knife or yard tool, or from a blunt force such as a fall, there may be a risk of infection. Urgent care providers are responsible for providing treatment that promotes healing and helps prevent wound infection. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you